Independent advisory Target Gordon Dyal & Co. Advisory Group LP for mid-market M&A advisory services and special situations, emphasizing discreet execution and long-term client relationships to expand deal origination with private equity and strategic buyers.

Biopharma focus Leverage the recent leadership change in biopharma M&A advisory to propose expansion services, cross-border mandates, or defense strategies for clients in biopharma and healthcare seeking strategic exits, partnerships, or activist defense.

Revenue signals Recognize mid-size revenue band and lean team dynamics as an opportunity to offer scalable technology-enabled deal execution, integration planning, and sell-side preparation to accelerate closings and reduce time to close.

Tech readiness Illustrate value through enhanced deal diligence, data room optimization, and client portal capabilities, aligning with Gordon Dyal & Co.’s current tech stack to deliver faster, more secure M&A processes.

Competitive landscape Position as a nimble, independent advisor in a field dominated by larger firms; target partnerships or sub-advisory arrangements with bigger players or investor clients seeking specialized execution and senior-level judgment.